Our Recommendations
- Notes de la Consultationsur le contrôle de l’utilisationen situation d’urgence d’interventions thérapeutiques non homologuées pour le traitementde la maladie à virus Ebola (MVE) (2018)
- Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD) (2018)
- Issue Brief Marburg virus disease (MVD) (2024)
New Publications
- Issue Brief Marburg virus disease (MVD) (2024)
- Marburg virus disease (2024)
- Factsheet for health professionals about Marburg virus disease (2024)
- Un vaccin efficace contre le virus Ebola est à portée de main (2015)
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial (2015)
Filter
34
Featured
Recommendations
3
New Publications
24
Language
Document type
No document type
31
Fact sheets
2
Training Material
1
Countries / Regions
Congo, Democratic Republic of
10
Guinea
5
Liberia
5
Uganda
3
Sierra Leone
2
Rwanda
2
West and Central Africa
2
South Sudan
2
Nigeria
1
Senegal
1
Authors & Publishers
Publication Years
Category
Countries
2
Clinical Guidelines
2
Key Resources
1
Toolboxes
Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to cause epidemics with significant case fatality rates.
Fact Sheet
Issue Brief Marburg virus disease (MVD)
recommended
Issue Brief No. 40 provides healthcare professionals with the most relevant treatment guidelines, prevention measures and training material on MVD
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...
An example of integration of research into epidemic response.
The Committee examined the clinical development of Ebola virus vaccines and conducted an inventory of available data on their safety. It also reviewed 3 generic issues: updating a global strategy on vaccine safety, use of a network of distributed data ...
Eurosurveillance. Vol. 23 (2018) Issue 9 (10 May 2018)
Researchers are devising a clinical-trial protocol to test three medicines in Africa's latest outbreak
Nature doi: 10.1038/d41586-018-06132-7
The Ministry of Health is working with WHO, Gavi, MSF, UNICEF and other partners to ring vaccinate high-risk populations in Ebola-affected health zones in the Democratic Republic of the Congo. As vaccine supplies arrive in Geneva ahead of deployment to Kinshasa, WHO’s Dr Peter Salama explains what...
PLoS Negl Trop Dis 11(2): e0005356 -Published: February 23, 2017 21 pp
This report describes the work done by WHO from January 2015 up to the end of December 2016 to address the long-term issues of survivor care, health-systems strengthening and research.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
The Lancet. Published Online December 22, 2016 http://dx.doi.org/10.1016/S0140-6736(16)32621-6. Open Access
